krysta pellegrino retweeted
At the @AASLDtweets’ #TLM26, Madrigal will present 18 abstracts spanning real-world evidence and clinical research in MASH.
These presentations reflect the breadth of our research and our continued commitment to generating rigorous evidence aimed at advancing the field and improving care.
View the full list of abstracts: ir.madrigalpharma.com/news-r…
krysta pellegrino retweeted
Today we announced a global license agreement for a clinical-stage, small interfering RNA (siRNA) asset targeting PNPLA3, a key genetic driver of MASH progression - strengthening our leadership in shaping the next generation of MASH therapies.
Small interfering RNAs (siRNAs) offer a precision approach to gene silencing by breaking down targeted mRNAs to selectively reduce the production of disease-driving proteins. Learn more: bit.ly/3OGoZek
A bold statement...but wow, imagine if that's where this leads. Looking forward to seeing all the data. endpoints.news/its-just-the-…
35
Sharon Mates, founder of Intra-Cellular on her "elevator advice" to young scientists: "dumb it down." If that isn't an endorsement for a good Communications team I don't know what is! #STATBreakthrough
krysta pellegrino retweeted
Today we announced a global license agreement for six pre-clinical siRNA programs. Read more about it and our expanded pipeline here: bit.ly/4bObS3H
krysta pellegrino retweeted
We’re expanding our pipeline with a new clinical-stage asset, strengthening our leadership in MASH.
Read more here: bit.ly/4qe3DlK
I loved every word of this article. I was expecting 2SP to be on the list though!
An unserious list of 10 places where CNN should hold Kamala Harris’ Delco town hall
From Pica's to Putt-Putt, these places have deep roots in "The champagne of burbs."
Thanks to all who offered amazing suggestions for my latest column!
share.inquirer.com/DLVymd
1
1
206
krysta pellegrino retweeted
The Backstory: During a visit to @StokeTx yesterday, we met co-founder @isa_aznarez and heard the story of how the company was founded and why the focus on gene expression upregulation.
See more at BiotechTV.com
krysta pellegrino retweeted
Behind the Science: @StokeTx's CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome. $STOK
Full video: biotechtv.com/post/stoke-the…
krysta pellegrino retweeted
Company News: @Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma.
Full video: biotechtv.com/post/adaptimmu…
krysta pellegrino retweeted
Our CMO Dr. David Cooper spoke with @neurology_live to discuss the details of ASPIRE-FTD, a Ph. 1/2 clinical trial evaluating our investigational #GeneTherapy for #FrontotemporalDementia with GRN mutations (FTD-GRN).
Learn more below.
#BioTech #Dementia
David Cooper, MD, of @AviadoBio, gave comment on some of the ongoing challenges associated with gene therapies in frontotemporal #dementia, and how the company will overcome these.
neurologylive.com/view/newly…
Loved this @PRDaily article about strategic media relations - this is what I try to practice and teach our #PR team. Critical to know what these influential reporters want & how they work to assess if a client can fit in.
prdaily.com/flip-the-script-…
43
krysta pellegrino retweeted
Our CEO Michael Parini sat down with @BiotechTVHQ for an insightful discussion about our recent rebrand, our approach to developing transformational gene therapies, and our mission to redefine what gene therapy can do for patients.
Company News: Stevenage, UK based @SpurTherapeutx is readying to take its gene therapy for Gaucher disease into phase 3.
Full video: biotechtv.com/post/spur-ther…
krysta pellegrino retweeted
Exciting announcement: Freeline is now Spur Therapeutics! We’re building on our successes to keep advancing the practice of genetic medicine, with the goal of bringing life-changing therapies to more people around the world.
Learn more: spurtherapeutics.com
Happy 10th anniversary Stoke! Amazing team of people doing great work to help patients and families with Dravet syndrome - lots to celebrate (and lots of work ahead!).
Cheers to 10 years of Stoke 🎉
In the last decade, we’ve made strides in our research, grown our pipeline, and cultivated a culture that strikes a balance between serious work and fun.
#StokedAboutStoke
2
101
Great interview with @AviadoBio CEO Lisa Deschamps explaining the company's investigational #genetherapy and unique delivery for #FTD, a devastating form of dementia. The new office and lab in Canary Wharf looks beautiful!
From London: Canary Wharf based @AviadoBio entered the clinic in April with the world's first-in-human intrathalamic delivered gene therapy for a type of dementia.
Full video: biotechtv.com/post/aviadobio…
1
105
Nice piece about late-breaking data from Freeline at #ASGCT2024 from its gene therapy study in #Gaucher disease endpts.com/freeline-unveils-…
1
144
👁 Heading to #ASCRS in Boston? Let’s connect! 👁️
I’m looking forward to reuniting with my fellow #eyecare enthusiasts and delving into the latest and greatest developments in #ophthalmology. Reach out!
#ASCRS2024
4
193
So proud of Mary - she is so driven to succeed, not just for herself but for those people and causes she cares about, including environmental causes. Thanks @LowerGwyneddPA for recognizing her!
Congratulations to our inaugural winners of the Lower Gwynedd Township EAC's Going Green Award!
Mary Pellegrino- Youth Award
Harth Builders - Honorable Mention
Gwynedd Friends School & Gwynedd Friends Monthly- Winner
8
498
krysta pellegrino retweeted
The preliminary #JPM24 schedule is out.






















